MX360665B - Nueva composición de alfentanilo para el tratamiento del dolor agudo. - Google Patents
Nueva composición de alfentanilo para el tratamiento del dolor agudo.Info
- Publication number
- MX360665B MX360665B MX2014013176A MX2014013176A MX360665B MX 360665 B MX360665 B MX 360665B MX 2014013176 A MX2014013176 A MX 2014013176A MX 2014013176 A MX2014013176 A MX 2014013176A MX 360665 B MX360665 B MX 360665B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- alfentanil
- acid
- new
- microparticles
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 title abstract 3
- 208000002193 Pain Diseases 0.000 title abstract 3
- 229960001391 alfentanil Drugs 0.000 title abstract 3
- 208000005298 acute pain Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000011859 microparticle Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000011872 intimate mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan composiciones farmacéuticas para el tratamiento del dolor, por ejemplo el dolor de corta duración, comprendiendo las composiciones una mezcla que comprende: (a) micropartículas de alfentanilo, o una sal farmacéuticamente aceptable del mismo, presentándose las micropartículas en las superficies de partículas vehículo más grandes; (b) una base débil soluble en agua; y (c) un compuesto que es un ácido débil, presentándose el ácido en mezcla íntima con las micropartículas de alfentanilo o la sal del mismo. La composición puede comprender además un disgregante. El ácido es, preferentemente, ácido cítrico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1207701.2A GB201207701D0 (en) | 2012-05-02 | 2012-05-02 | New pharmaceutical composition |
| GBGB1221130.6A GB201221130D0 (en) | 2012-11-23 | 2012-11-23 | New pharmaceutical composition |
| PCT/GB2013/051131 WO2013164620A1 (en) | 2012-05-02 | 2013-05-01 | New alfentanil composition for the treatment of acute pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013176A MX2014013176A (es) | 2015-01-19 |
| MX360665B true MX360665B (es) | 2018-11-13 |
Family
ID=48577134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013176A MX360665B (es) | 2012-05-02 | 2013-05-01 | Nueva composición de alfentanilo para el tratamiento del dolor agudo. |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US8815911B2 (es) |
| EP (2) | EP3150199B1 (es) |
| JP (1) | JP6275696B2 (es) |
| KR (1) | KR20150005695A (es) |
| CN (1) | CN104427978B (es) |
| AU (1) | AU2013255640B2 (es) |
| BR (1) | BR112014027213A8 (es) |
| CA (1) | CA2871805A1 (es) |
| CL (1) | CL2014002979A1 (es) |
| CO (1) | CO7170181A2 (es) |
| CY (2) | CY1118570T1 (es) |
| DK (2) | DK3150199T3 (es) |
| EA (1) | EA028110B1 (es) |
| ES (2) | ES2614757T3 (es) |
| HR (2) | HRP20161634T1 (es) |
| HU (1) | HUE031792T2 (es) |
| IL (1) | IL235272B (es) |
| IN (1) | IN2014MN02156A (es) |
| LT (2) | LT2849730T (es) |
| ME (1) | ME02644B (es) |
| MX (1) | MX360665B (es) |
| NZ (1) | NZ701428A (es) |
| PE (1) | PE20142444A1 (es) |
| PH (1) | PH12014502407A1 (es) |
| PL (2) | PL3150199T3 (es) |
| PT (2) | PT2849730T (es) |
| RS (2) | RS57951B1 (es) |
| SG (1) | SG11201407081PA (es) |
| SI (2) | SI2849730T1 (es) |
| SM (3) | SMT201800585T1 (es) |
| TR (1) | TR201815935T4 (es) |
| WO (1) | WO2013164620A1 (es) |
| ZA (1) | ZA201407559B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX361757B (es) | 2011-09-19 | 2018-12-13 | Orexo Ab | Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides. |
| SG11201407081PA (en) * | 2012-05-02 | 2014-11-27 | Orexo Ab | New alfentanil composition for the treatment of acute pain |
| US10766925B2 (en) * | 2016-04-11 | 2020-09-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Opioid receptor modulators |
| JP7023054B2 (ja) * | 2017-04-05 | 2022-02-21 | 東和薬品株式会社 | レベチラセタム含有医薬組成物及びその製造方法 |
| CN115047109B (zh) * | 2022-06-17 | 2024-05-31 | 三明海关综合技术服务中心 | 一种检测食品中芬太尼类新精神活性物质的方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| DE19749724A1 (de) | 1997-11-11 | 1999-06-10 | Gruenenthal Gmbh | Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln |
| SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9904911D0 (en) | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20020160043A1 (en) | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| JP4850346B2 (ja) | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
| US20030068356A1 (en) | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| WO2004067004A1 (en) | 2003-01-31 | 2004-08-12 | Orexo Ab | A rapid-acting pharmaceutical composition |
| WO2004075877A1 (en) | 2003-02-24 | 2004-09-10 | Pharmaceutical Productions, Inc. | Transmucosal drug delivery system |
| US20050042281A1 (en) | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
| CA2549642C (en) | 2003-12-31 | 2012-10-30 | Cima Labs Inc. | Effervescent oral opiate dosage forms and methods of administering opiates |
| WO2005065319A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| US7858121B2 (en) * | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| US20070036853A1 (en) | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| CA2599386A1 (en) | 2005-03-28 | 2006-10-05 | Orexo Ab | New pharmaceutical compositions useful in the treatment of pain |
| US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8535714B2 (en) * | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US20100233257A1 (en) | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
| US20070286900A1 (en) | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
| SI2054031T1 (sl) * | 2006-07-21 | 2016-09-30 | Biodelivery Sciences International, Inc. | Transmukozne naprave za administracijo z izboljšanim vnosom |
| US8470361B2 (en) * | 2006-12-04 | 2013-06-25 | Orexo Ab | Non-abusable pharmaceutical composition comprising opioids |
| EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| KR101606944B1 (ko) | 2007-08-07 | 2016-03-28 | 아셀알엑스 파마슈티컬스 인코퍼레이티드 | 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법 |
| US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
| US8343978B2 (en) | 2008-08-04 | 2013-01-01 | Adds Pharmaceuticals Llc | Fast onset orodispersable tablets |
| US20100056574A1 (en) | 2008-09-04 | 2010-03-04 | Mallinckrodt Inc. | Crystalline Forms of Sufentanil |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| JP2012526840A (ja) | 2009-05-13 | 2012-11-01 | プロテイン デリヴァリー ソリューションズ エルエルシー | 膜貫通送達のための製剤系 |
| WO2010141505A1 (en) | 2009-06-01 | 2010-12-09 | Protect Pharmaceutical Corporation | Abuse-resistant delivery systems |
| JP2009280611A (ja) * | 2009-08-26 | 2009-12-03 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜フィルム剤 |
| US20110091544A1 (en) | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| US20110262442A1 (en) | 2009-11-06 | 2011-10-27 | Adenios, Inc. | Compositions for treating cns disorders |
| US20110150989A1 (en) | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
| SG11201407081PA (en) * | 2012-05-02 | 2014-11-27 | Orexo Ab | New alfentanil composition for the treatment of acute pain |
-
2013
- 2013-05-01 SG SG11201407081PA patent/SG11201407081PA/en unknown
- 2013-05-01 TR TR2018/15935T patent/TR201815935T4/tr unknown
- 2013-05-01 CN CN201380022630.2A patent/CN104427978B/zh not_active Expired - Fee Related
- 2013-05-01 DK DK16197166.8T patent/DK3150199T3/en active
- 2013-05-01 PL PL16197166T patent/PL3150199T3/pl unknown
- 2013-05-01 PE PE2014001937A patent/PE20142444A1/es not_active Application Discontinuation
- 2013-05-01 US US13/874,762 patent/US8815911B2/en not_active Expired - Fee Related
- 2013-05-01 MX MX2014013176A patent/MX360665B/es active IP Right Grant
- 2013-05-01 CA CA2871805A patent/CA2871805A1/en not_active Abandoned
- 2013-05-01 RS RS20181295A patent/RS57951B1/sr unknown
- 2013-05-01 ES ES13727314.0T patent/ES2614757T3/es active Active
- 2013-05-01 EP EP16197166.8A patent/EP3150199B1/en active Active
- 2013-05-01 LT LTEP13727314.0T patent/LT2849730T/lt unknown
- 2013-05-01 SM SM20180585T patent/SMT201800585T1/it unknown
- 2013-05-01 EP EP13727314.0A patent/EP2849730B1/en active Active
- 2013-05-01 SI SI201330490A patent/SI2849730T1/sl unknown
- 2013-05-01 NZ NZ701428A patent/NZ701428A/en not_active IP Right Cessation
- 2013-05-01 HR HRP20161634TT patent/HRP20161634T1/hr unknown
- 2013-05-01 AU AU2013255640A patent/AU2013255640B2/en not_active Ceased
- 2013-05-01 SI SI201331238T patent/SI3150199T1/sl unknown
- 2013-05-01 KR KR1020147033700A patent/KR20150005695A/ko not_active Ceased
- 2013-05-01 HU HUE13727314A patent/HUE031792T2/en unknown
- 2013-05-01 SM SM20170086T patent/SMT201700086T1/it unknown
- 2013-05-01 LT LTEP16197166.8T patent/LT3150199T/lt unknown
- 2013-05-01 PT PT137273140T patent/PT2849730T/pt unknown
- 2013-05-01 ME MEP-2017-9A patent/ME02644B/me unknown
- 2013-05-01 ES ES16197166.8T patent/ES2694644T3/es active Active
- 2013-05-01 PT PT16197166T patent/PT3150199T/pt unknown
- 2013-05-01 IN IN2156MUN2014 patent/IN2014MN02156A/en unknown
- 2013-05-01 JP JP2015509496A patent/JP6275696B2/ja not_active Expired - Fee Related
- 2013-05-01 BR BR112014027213A patent/BR112014027213A8/pt not_active Application Discontinuation
- 2013-05-01 WO PCT/GB2013/051131 patent/WO2013164620A1/en not_active Ceased
- 2013-05-01 EA EA201401200A patent/EA028110B1/ru not_active IP Right Cessation
- 2013-05-01 PL PL13727314T patent/PL2849730T3/pl unknown
- 2013-05-01 DK DK13727314.0T patent/DK2849730T3/en active
- 2013-05-01 RS RS20161161A patent/RS55489B1/sr unknown
-
2014
- 2014-07-15 US US14/331,507 patent/US9345698B2/en not_active Expired - Fee Related
- 2014-10-17 ZA ZA2014/07559A patent/ZA201407559B/en unknown
- 2014-10-22 IL IL235272A patent/IL235272B/en not_active IP Right Cessation
- 2014-10-27 PH PH12014502407A patent/PH12014502407A1/en unknown
- 2014-10-29 CO CO14239767A patent/CO7170181A2/es not_active Application Discontinuation
- 2014-11-03 CL CL2014002979A patent/CL2014002979A1/es unknown
-
2016
- 2016-04-26 US US15/138,570 patent/US9782396B2/en not_active Expired - Fee Related
-
2017
- 2017-01-31 CY CY20171100139T patent/CY1118570T1/el unknown
- 2017-02-08 SM SM201700086T patent/SMT201700086B/it unknown
- 2017-09-11 US US15/701,300 patent/US20180214437A1/en not_active Abandoned
-
2018
- 2018-10-25 HR HRP20181761TT patent/HRP20181761T1/hr unknown
- 2018-11-05 CY CY181101154T patent/CY1120820T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| IN2014DN10670A (es) | ||
| MX351584B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
| NZ721952A (en) | Delayed release compositions of linaclotide | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| AU2013373885B2 (en) | Oxazolidone compound, preparing method and application thereof | |
| MX362489B (es) | Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa. | |
| PH12014501991B1 (en) | Phenicol antibacterials | |
| IN2015DN01164A (es) | ||
| EA201490760A1 (ru) | R(+)-n-метилпропаргиламиноиндан | |
| IL222578A0 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| IN2015DN01165A (es) | ||
| WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| PH12014502407A1 (en) | New alfentanil composition for the treatment of acute pain | |
| EA201401309A1 (ru) | Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение | |
| MX2013010947A (es) | Complejos de galio, composiciones farmacéuticas y métodos de uso. | |
| MX2014006201A (es) | Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse. | |
| EA201201329A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| IN2013MU03428A (es) | ||
| GB201004677D0 (en) | New salt | |
| WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |